The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
January 24th 2025
The report highlights perspective from 4 key stakeholders of patients, specialty pharmacies and providers, biopharmaceutical industry, and public and private payers.
Triggering a Tumor Antiviral Immune Response in Patients With Triple-Negative Breast Cancer
January 22nd 2021During a study investigating therapeutics that target how RNA splicing activates antiviral immune pathways in triple-negative breast cancers, researchers observed that endogenous RNA in tumor cells that had been mis-spliced is able to mimic an RNA virus.
Read More
Study: Sharp Decline in Cancer Screenings, Diagnoses During the First COVID-19 Surge
January 21st 2021The study findings emphasize the need for people who missed or postponed a cancer screening test early in the pandemic to contact their health care provider to discuss the potential need to reschedule it, according to the study authors.
Read More
FDA Grants Priority Review to Treatment for Resected Esophageal or Gastroesophageal Junction Cancer
January 21st 2021FDA grant priority review to a supplemental biologics license application for nivolumab (Opdivo) for use as an adjuvant treatment for patients with resected esophageal or gastroesophageal junction cancer.
Read More
FDA Fast Tracks Padeliporfin Immune Photo Activated Cancer Therapy for Upper-Tract Urothelial Cancer
January 19th 2021A minimally invasive, targeted treatment option, ImPACT is also under evaluation in patients with other localized tumors, such as urothelial cancer, esophageal cancer, lung cancer, and pancreatic cancer.
Read More
Study: Biologic Therapy for Psoriasis May Reduce Heart Disease
January 12th 2021The current study provides characterization of a lipid-rich necrotic core, a dangerous type of coronary plaque made up of dead cells and cell debris that is prone to rupture, which can lead to a heart attack or stroke.
Read More
Risankizumab Demonstrates Significant Improvements In Patients with Crohn Disease
January 11th 2021A significantly greater proportion of patients with Crohn disease achieved both primary endpoints with overall safety results generally consistent with the known safety profile of risankizumab.
Read More